Welcome to our dedicated page for CURATIVE BIOTECHNOLOGY news (Ticker: CUBT), a resource for investors and traders seeking the latest updates and insights on CURATIVE BIOTECHNOLOGY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CURATIVE BIOTECHNOLOGY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CURATIVE BIOTECHNOLOGY's position in the market.
Curative Biotechnology (OTC: CUBT), a development-stage biomedical company specializing in treatments for degenerative eye diseases, has announced the appointment of Golden Eagle Capital Advisors (GECA) as its exclusive agent and strategic advisor. GECA, a Dubai-based financial advisory group, will provide strategic guidance to support CUBT's business objectives.
Curative Biotechnology Inc. (CUBT) announced on January 5, 2023, the successful completion of its IND enabling Tolerance and Toxicology Study of Metformin HCL Solution for eye drop use in rabbits. This milestone allows the company to prepare its IND application for a clinical trial targeting Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographic Atrophy (GA). The studies address unmet medical needs, as no FDA-approved treatments currently exist for these conditions. The first human study will be conducted under a CRADA with the National Eye Institute.
Curative Biotechnology Inc. (CUBT) announced plans for an underwritten public offering of its common stock, following a 1-for-400 reverse stock split. The offering may include a 45-day option for the underwriter to purchase an additional 15% of shares. Proceeds will be allocated for working capital and corporate purposes. The offering is subject to market conditions and is expected to close by September 30, 2022, with trading on the NYSE American set to begin on October 3, 2022. Aegis Capital Corp. is the sole book-running manager for this offering.
Curative Biotechnology Inc. (OTC: CUBT) has appointed Lawrence S. Zaslow as an independent director, enhancing its Board of Directors. Zaslow, a co-founder of BioTheryX, Inc., brings extensive experience in strategic planning, capital raising, and corporate development. His leadership contributed to BioTheryX's $100 million financing round. Curative Biotech focuses on novel treatments for rare diseases, with ongoing programs in infectious disease, neuro oncology, and degenerative eye disease, including its pipeline candidates IMT504, CURB906, and a reformulated Metformin for Age-Related Macular Degeneration.
Curative Biotechnology Inc. (CUBT) announced the appointment of Cary Sucoff as an independent director on May 12, 2022. Sucoff brings over 35 years of experience in legal and securities sectors, having participated in financing for more than 100 public and private companies. His expertise encompasses legal compliance, corporate strategy, and capital markets. Sucoff is also involved with several healthcare and biotech firms, enhancing Curative Biotech's financial governance and oversight capabilities.
FAQ
What is the current stock price of CURATIVE BIOTECHNOLOGY (CUBT)?
What is the market cap of CURATIVE BIOTECHNOLOGY (CUBT)?
